Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Epicenter who wrote (1702)	2/4/1999 1:17:00 PM
From: M. Ramle	Read Replies (2) \| Respond to of 10280

Epicenter: My take on the down-days with low-volume is very bullish. Technically, the chart looks absolutely beautiful, and my indicators point to a forthcoming breakout towards the $128-130 near-term. Just buy on any dips around the $110 area for now. GOOD LUCK TO ALL. Mazen PS. Teabury22 - Bruce - Ed - Bob: Thanks for the welcoming posts. Boy, this is what I call "ROYALTY WELCOME TREATMENT" !!!!!!!

To: Epicenter who wrote (1702)	2/4/1999 1:29:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Epicenter, Strikes me that the stock has held up amazingly well in the face of a downgrade which also claimed that Xopenex would only be available next quarter. We've also seen downgrades based on price in other first/second tier biotechs. Part of the recent move up might have been short covering - see the Jesse Eisinger article at Thestreet describing how the (misguided) 2nd-tier biotech short sellers had finally thrown in the towel. Maybe some of the recent failures (CLPA, NRGN) have reminded people that SEPR's risks are considerably less for its pipeline. As you point out, there's been no news of late, and so it's just us long-term holders and institutions left - just the way I like it. <G> Peter